Results 181 to 190 of about 4,844,901 (248)

Necrotizing Soft Tissue Infection of the Upper Extremity as a Manifestation of Hansen's Disease. [PDF]

open access: yesJ Hand Surg Glob Online, 2022
Bougioukli S   +5 more
europepmc   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

open access: yesBritish Journal of Haematology, EarlyView.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl   +23 more
wiley   +1 more source

Hansen's Disease in Ecuador: Current Status, Knowledge Gaps, and Research Priorities: A Literature Review. [PDF]

open access: yesPathogens
Calvopiña M   +5 more
europepmc   +1 more source

IMPACT OF HUMAN POPULATION ON ZOONOTIC DISEASE TRANSMISSION: A 22-YEAR REVIEW (2000-2022) OF RABIES, LYME DISEASE, AND HANSEN’S DISEASE IN FLORIDA

open access: yes
The Earth thrives under One-Health, a balance between humans, other animals, and environmental health. Zoonotic diseases can impact this equilibrium.
Kahl, Margaret
core  

Association of bi‐parametric MRI measures with continence after robot‐assisted radical prostatectomy

open access: yesBJU International, Volume 135, Issue 4, Page 603-610, April 2025.
Objective To investigate the association between pre‐ and postoperative magnetic resonance imaging (MRI) measurements of the membranous urethra and the prostate volume and continence following robot‐assisted radical prostatectomy (RARP). Patients and Methods From December 2018 to June 2022, 100 continent patients undergoing unilateral nerve‐sparing or ...
Alexander B. Nolsøe   +8 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown   +2 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Home - About - Disclaimer - Privacy